Correspondence 0001104659-23-047751 from ProQR Therapeutics N.V. (PRQR)
ProQR Therapeutics N.V.
Date: April 20, 2023 · CIK: 0001612940 · Accession: 0001104659-23-047751
AI Filing Summary & Sentiment
File numbers found in text: 333-270943
Letter
VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Attention: Arzhang Navai Re: ProQR Therapeutics N.V. Acceleration Request for Registration Statement on Form F-3 File No. 333-270943
Dear Arzhang Navai:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), ProQR Therapeutics N.V. (the “Company”) hereby requests that the effective date and time of the above-referenced registration statement (the “Registration Statement”) be accelerated to April 24, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as possible. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling James Xu at (650) 752-3355. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “Commission”) verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: James Xu, by email to JXu@goodwinlaw.com.
If you have any questions regarding this request, please contact James Xu of Goodwin Procter LLP at (650) 752-3355.
[Signature Page Follows]
Sincerely,
pROQR thERAPEUTICS N.V.
Show Raw Text
CORRESP
1
filename1.htm
PROQR THERAPEUTICS N.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
VIA EDGAR AND FEDERAL EXPRESS
April 20, 2023
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Arzhang Navai
Re: ProQR Therapeutics N.V.
Acceleration Request for Registration Statement on Form F-3
File No. 333-270943
Dear Arzhang Navai:
Pursuant to
Rule 461 under the Securities Act of 1933, as amended (the “Act”), ProQR Therapeutics N.V. (the
“Company”) hereby requests that the effective date and time of the above-referenced registration statement (the
“Registration Statement”) be accelerated to April 24, 2023, at 4:00 p.m., Eastern Time, or as soon
thereafter as possible. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under
the Act.
Once the Registration Statement
is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling James Xu at (650) 752-3355. We also respectfully
request that a copy of the written order from the Securities and Exchange Commission (the “Commission”) verifying the
effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: James Xu, by email to JXu@goodwinlaw.com.
If you have any
questions regarding this request, please contact James Xu of Goodwin Procter LLP at (650) 752-3355.
[Signature Page Follows]
Sincerely,
pROQR thERAPEUTICS N.V.
/s/ René Beukema
René Beukema
Chief Corporate Development Officer and General Counsel
cc:
Jurriaan Dekkers, ProQR Therapeutics N.V.
Mitchell S. Bloom, Goodwin Procter LLP
Danielle M. Lauzon, Goodwin Procter LLP
James Xu, Goodwin Procter LLP
[Signature Page to Acceleration Request]